Lanreotide is a synthetic peptide that mimics somatostatin, a natural hormone that suppresses the release of several other hormones throughout the body. Sold in the U.S. under the brand name Somatuline Depot, it's one of two FDA-approved somatostatin analog peptides discussed on this site, the other being octreotide, covered in this site's dedicated octreotide guide.
What It Is and How It Works
Lanreotide binds to somatostatin receptors, primarily the type-2 receptor subtype concentrated on certain hormone-secreting cells. By activating these receptors, it suppresses the release of growth hormone, insulin-like growth factor 1 (IGF-1), and several gut hormones. It's formulated as a long-acting, deep subcutaneous injection, administered by a healthcare provider on a monthly schedule rather than self-administered daily.
FDA-Approved Uses
Lanreotide (Somatuline Depot) received its first FDA approval in 2007 for the long-term treatment of acromegaly, a condition caused by excess growth hormone, typically from a pituitary tumor, in patients who haven't responded adequately to surgery or radiotherapy, or for whom those options aren't appropriate. The FDA expanded its approval in 2014 to include gastroenteropancreatic neuroendocrine tumors (GEP-NETs), where it's used to slow tumor growth in patients with unresectable, locally advanced, or metastatic disease. Both indications are on-label, FDA-approved uses, not off-label applications.
How It Compares to Octreotide
Octreotide, approved earlier, targets a similar set of somatostatin receptors and is approved for overlapping indications, acromegaly and certain neuroendocrine tumors, among others. The two drugs are generally considered therapeutically similar in mechanism and approved uses, and the choice between them in practice often comes down to formulation, dosing schedule, and physician or institutional preference rather than a meaningful difference in effectiveness. Neither is interchangeable with the other without a prescriber's involvement, since they aren't formally classified as generic equivalents of each other.
What the Clinical Evidence Shows
Lanreotide's approval rests on randomized, placebo-controlled human trials, not animal data alone, the same evidentiary bar required for any FDA-approved drug. In acromegaly, trials demonstrated its ability to normalize or substantially lower IGF-1 and growth hormone levels in a meaningful share of patients. In the CLARINET trial, the pivotal study supporting its GEP-NET indication, lanreotide significantly extended progression-free survival compared with placebo in patients with certain non-functioning tumors.
Safety Considerations
Like other somatostatin analogs, lanreotide can affect blood sugar regulation in both directions, and patients with diabetes may need their glucose-lowering medications adjusted while on treatment. Gallbladder-related side effects, including gallstones, are a recognized risk with long-term somatostatin analog use, and the drug can also slow heart rate and affect thyroid function over time. As with any prescription peptide therapy, these risks should be discussed with and monitored by the prescribing physician, not managed independently. Because it's given by injection at a clinic or infusion center rather than self-administered at home, routine lab monitoring, including blood glucose and thyroid function, is typically built into the treatment schedule itself.
The Bottom Line
Lanreotide is a well-established, FDA-approved peptide drug with a defined mechanism, two specific approved indications, and a clinical trial record supporting both. It's a useful example of how peptide therapeutics have had a role in endocrinology and oncology well before GLP-1 drugs brought the broader category into the mainstream conversation.